In the interim found the RELY study of dabigatran in acute coronary syndromes. Looks like an excess of MI in the treatment group, looks like we don't have to worry yet. Dag, however will replace coumdin in Afib for sure. bp
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.